MSH|^~\&|LAB|ARH|||201911131306||ORU^R01|4104457|D|2.3|||AL|NE
PID|1||AB00008255|AB8154|LABTEST^HFE8^||19680808|M||||||||||AB000505/19|
OBR|1|35136^LAB|00026986^1311:C00012R^LAB^131119:C12^35136|220.5080^HFE CD^Hemochromatosis-Conf Diagnosis^^^XXX-1182||201911130856|201911130857|||||||201911130857||||||||||LAB|I||||
OBR|2|35136^LAB|00026986^1311:C00012R^LAB^131119:C12^35136|520.4200^IRON^Iron Studies Profile^^^50190-8||201911130856|201911130857|||||||201911130857||||||||||LAB|F||||
OBX|1|ST|520.4300^FE^Iron^^14798-3^14798-3|1|20^^Y|umol/L|9-30|N||A^S|F|||201911131305
OBX|2|ST|520.4500^TIBC^Total Iron Binding Capacity^^14800-7^14800-7|1|33^^Y|umol/L|45-70|L||A^S|F|||201911131305
OBX|3|ST|520.4600^TRFSAT^Transferrin Saturation^^6796-7^14801-5|1|0.61^^Y||0.15-0.55|H||A^S|F|||201911131305
NTE|1||Markedly elevated transferrin saturation.  Follow up and
NTE|2||management as per BCMA/MSP Iron Overload protocol.

MSH|^~\&|LAB|ARH|||201911131309||ORU^R01|4104460|D|2.3|||AL|NE
PID|1||AB00008255|AB8154|LABTEST^HFE8^||19680808|M||||||||||AB000505/19|
OBR|1|35136^LAB|00026986^1311:C00012R^LAB^131119:C12^35136|220.5080^HFE CD^Hemochromatosis-Conf Diagnosis^^^XXX-1182||201911130856|201911130857|||||||201911130857||||||||||LAB|F||||
OBX|1|ST|520.4700^FER^Ferritin^^2276-4^2276-4|1|533^^Y|ug/L|15-370|H||A^S|F|||201911131309
OBR|2|35136^LAB|00026986^1311:C00012R^LAB^131119:C12^35136|520.4200^IRON^Iron Studies Profile^^^50190-8||201911130856|201911130857|||||||201911130857||||||||||LAB|F||||
OBX|1|ST|520.4300^FE^Iron^^14798-3^14798-3|1|20^^Y|umol/L|9-30|N||A^S|F|||201911131305
OBX|2|ST|520.4500^TIBC^Total Iron Binding Capacity^^14800-7^14800-7|1|33^^Y|umol/L|45-70|L||A^S|F|||201911131305
OBX|3|ST|520.4600^TRFSAT^Transferrin Saturation^^6796-7^14801-5|1|0.61^^Y||0.15-0.55|H||A^S|C|||201911131309
NTE|1||   ****   CORRECTED RESULT  ****
NTE|2||   ---  13/11/19 1307 ---
NTE|3||  TRFSAT previously reported as: 0.61  H
NTE|4||
NTE|5||
NTE|6||Hyperferritinemia and elevated transferrin saturation index:
NTE|7||Patient meets criteria for HFE genetic testing as specified
NTE|8||in the current BC Guidelines.
NTE|9||Markedly elevated transferrin saturation.  Follow up and
NTE|10||management as per BCMA/MSP Iron Overload protocol.
OBR|3|35136^LAB|00026986^1311:C00012R^LAB^131119:C12^35136|520.4720^HFE HH^Hemochromatosis^^^XXX-1182||201911130856|201911130857|||||||201911130857||||||||||LAB|I||||

MSH|^~\&|LAB|ARH|||201911131311||ORU^R01|4104461|D|2.3|||AL|NE
PID|1||AB00008254|AB8153|LABTEST^HFE7^||19770707|F||||||||||AB000504/19|
OBR|1|35154^LAB|00026996^1311:C00023R^LAB^131119:C23^35154|220.5080^HFE CD^Hemochromatosis-Conf Diagnosis^^^XXX-1182||201911131135|201911131135|||||||201911131135||||||||||LAB|I||||
OBR|2|35154^LAB|00026996^1311:C00023R^LAB^131119:C23^35154|520.4200^IRON^Iron Studies Profile^^^50190-8||201911131135|201911131135|||||||201911131135||||||||||LAB|F||||
OBX|1|ST|520.4300^FE^Iron^^14798-3^14798-3|1|20^^Y|umol/L|9-30|N||A^S|F|||201911131311
OBX|2|ST|520.4500^TIBC^Total Iron Binding Capacity^^14800-7^14800-7|1|33^^Y|umol/L|45-70|L||A^S|F|||201911131311
OBX|3|ST|520.4600^TRFSAT^Transferrin Saturation^^6796-7^14801-5|1|0.61^^Y||0.15-0.55|H||A^S|F|||201911131311
NTE|1||Markedly elevated transferrin saturation.  Follow up and
NTE|2||management as per BCMA/MSP Iron Overload protocol.

MSH|^~\&|LAB|DH|||201911131312||ORU^R01|4104462|D|2.3|||AL|NE
PID|1||DH00002091|AB7380|LABGOLD^TRAIN^AIDAN||19630201|M||||||||||DH000028/18|9879192668
OBR|1|35156^LAB|00026998^1311:H00001R^LAB^131119:H1^35156|200.1000^CBC^Hematology Cell Panel^^^XCA01592-5||201911131308|201911131308|||||||201911131308||||||||||LAB|F||||
OBX|1|ST|200.1700^RBC^Red Blood Cell Count^^789-8^789-8|1|4.33^^Y|x10*12/L|4.30-5.90|N||A^S|F|||201911131312
OBX|2|ST|200.1800^HB^Hemoglobin^^718-7^718-7|1|120^^Y|g/L|135-180|L||A^S|F|||201911131312
OBX|3|ST|200.2000^HCT^Hematocrit^^4544-3^4544-3|1|0.41^^Y|L/L|0.41-0.52|N||A^S|F|||201911131312
OBX|4|ST|200.2100^MCV^Mean Corpuscular Volume^^787-2^787-2|1|88^^Y|fL|80-100|N||A^S|F|||201911131312
OBX|5|ST|200.2500^PLT^Platelet Count^^777-3^777-3|1|160^^Y|x10*9/L|150-400|N||A^S|F|||201911131312
OBX|6|ST|200.3100^NE#^Absolute Neutrophils^^751-8^26499-4|1|2.0^^Y|x10*9/L|2.0-8.0|N||A^S|F|||201911131312
OBX|7|ST|200.3300^LY#^Absolute Lymphocytes^^731-0^26474-7|1|1.0^^Y|x10*9/L|1.0-4.0|N||A^S|F|||201911131312
OBX|8|ST|200.3400^MO#^Absolute Monocytes^^742-7^26484-6|1|0.1^^Y|x10*9/L|0.1-0.8|N||A^S|F|||201911131312
OBR|2|35156^LAB|00026998^1311:H00001R^LAB^131119:H1^35156|200.1200^BFE^Blood Film Examination^^^XCA01591-7||201911131308|201911131308|||||||201911131308||||||||||LAB|D||||
OBR|3|35156^LAB|00026998^1311:H00001R^LAB^131119:H1^35156|210.1900^HBPATHYP^Hemoglobinopathy Investigation^^^XXX-1989||201911131308|201911131308|||||||201911131308||||||||||LAB|I||||
OBX|1|ST|210.2055^MCH1^MCH for HBPATHY^785-6^785-6^785-6|1|29^^Y|pg|27-31|N||A^S|F|||201911131312

MSH|^~\&|LAB|ARH|||201911131312||ORU^R01|4104463|D|2.3|||AL|NE
PID|1||AB00008254|AB8153|LABTEST^HFE7^||19770707|F||||||||||AB000504/19|
OBR|1|35154^LAB|00026996^1311:C00023R^LAB^131119:C23^35154|220.5080^HFE CD^Hemochromatosis-Conf Diagnosis^^^XXX-1182||201911131135|201911131135|||||||201911131135||||||||||LAB|F||||
OBX|1|ST|520.4700^FER^Ferritin^^2276-4^2276-4|1|533^^Y|ug/L|15-200|H||A^S|F|||201911131312
OBR|2|35154^LAB|00026996^1311:C00023R^LAB^131119:C23^35154|520.4200^IRON^Iron Studies Profile^^^50190-8||201911131135|201911131135|||||||201911131135||||||||||LAB|F||||
OBX|1|ST|520.4300^FE^Iron^^14798-3^14798-3|1|20^^Y|umol/L|9-30|N||A^S|F|||201911131311
OBX|2|ST|520.4500^TIBC^Total Iron Binding Capacity^^14800-7^14800-7|1|33^^Y|umol/L|45-70|L||A^S|F|||201911131311
OBX|3|ST|520.4600^TRFSAT^Transferrin Saturation^^6796-7^14801-5|1|0.61^^Y||0.15-0.55|H||A^S|C|||201911131312
NTE|1||Hyperferritinemia and elevated transferrin saturation index:
NTE|2||Patient meets criteria for HFE genetic testing as specified
NTE|3||in the current BC Guidelines.
NTE|4||Markedly elevated transferrin saturation.  Follow up and
NTE|5||management as per BCMA/MSP Iron Overload protocol.